menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Poster Pearl: Improved Sensitivity of a Multi-Analyte Early Detection Test Based on Mutation, Methylation, Aneuploidy, & Protein Biomarkers

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Sponsored by

  • Overview

    A poster presented at the 2022 American Association for Cancer Research Special Conference on Precision Prevention, Early Detection, and Interception of Cancer found that a four-biomarker class multi-cancer early detection (MCED) test configuration had higher overall sensitivity and specificity compared to a three-biomarker test configuration. These results imply that more early-stage cancers could be detected. Dive further into the data and results with Dr. Charles Turck and Dr. Frank Diehl, Senior Vice President of Multi-Cancer Early Detection at Exact Sciences Corporation and co-author of the poster.

    This is a non-certified educational series produced and controlled by ReachMD. This series is intended for healthcare professionals only. This program discusses a technology under development. Any features discussed describe current development goals. It has not been cleared or approved by the U.S. FDA or any other national regulatory authority.

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Sponsored by

  • Overview

    A poster presented at the 2022 American Association for Cancer Research Special Conference on Precision Prevention, Early Detection, and Interception of Cancer found that a four-biomarker class multi-cancer early detection (MCED) test configuration had higher overall sensitivity and specificity compared to a three-biomarker test configuration. These results imply that more early-stage cancers could be detected. Dive further into the data and results with Dr. Charles Turck and Dr. Frank Diehl, Senior Vice President of Multi-Cancer Early Detection at Exact Sciences Corporation and co-author of the poster.

    This is a non-certified educational series produced and controlled by ReachMD. This series is intended for healthcare professionals only. This program discusses a technology under development. Any features discussed describe current development goals. It has not been cleared or approved by the U.S. FDA or any other national regulatory authority.

Facebook Comments

Schedule20 Apr 2024